Viral resistens over for abacavir udvikles relativt langsomt in vitro og kræver multiple mutationer for at nå en klinisk relevant stigning i EC50 i forhold til vildtype virus.
Viral resistance to abacavir develops relatively slowly in vitro, requiring multiple mutations for a clinically relevant increase in EC50 over wild-type virus.